Tonix Pharmaceuticals Holding Corp. announced that its management team will participate in two upcoming investor conferences in March 2026. Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, from 11:10 a.m. to 11:40 a.m. ET at the Boston Marriott Copley Place in Boston. In addition, management will participate in one-on-one meetings at the Barclays 28th Annual Healthcare Conference, scheduled for March 10-12, 2026, at the Loews Miami South Beach Hotel in Miami Beach.
The company’s participation in these high-profile investor events comes at a significant time for Tonix Pharmaceuticals, which has transitioned to a commercial-stage biotechnology company. The company focuses on central nervous system and immunology treatments in areas of high unmet medical need. TONMYA, the company’s recently approved flagship medicine, represents the first new treatment for fibromyalgia in more than 15 years, marking a notable advancement in a therapeutic area that has seen limited innovation.
Beyond its commercial products, Tonix is actively developing its pipeline across multiple indications. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. This expansion into additional CNS conditions could significantly broaden the drug’s therapeutic impact and market potential. The company’s CNS portfolio also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease with limited treatment options.
Tonix’s immunology pipeline represents another important growth area for the company. The pipeline includes monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs address significant medical needs in infectious disease and transplant medicine, potentially creating additional value drivers for the company beyond its CNS focus.
The company’s commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. This established commercial capability provides a foundation for launching and supporting additional products as they progress through development and regulatory review. The latest news and updates relating to Tonix Pharmaceuticals are available in the company’s newsroom at https://ibn.fm/TNXP.
Investor conferences like those hosted by TD Cowen and Barclays provide important platforms for biotechnology companies to communicate their progress, strategy, and value proposition to the investment community. For Tonix, these presentations offer an opportunity to highlight both its commercial achievements and its development pipeline to potential investors and analysts. The company’s participation in these events reflects its ongoing efforts to maintain visibility and engagement with the financial markets as it executes on its strategic objectives across both commercial and development activities.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Tonix Pharmaceuticals to Present at Major Healthcare Investor Conferences in March 2026.